Stargardt disease (STGD) is a rare retinal disorder inherited in an autosomal recessive pattern. Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. It typically develops during childhood or adolescence, but the age of onset and rate of progression can vary.
The most common symptom of Stargardt disease is the variable, often slow loss of central vision in both eyes. The progression of symptoms in Stargardt disease is different for each person. People with an earlier onset of diseases tend to have more rapid vision loss. Currently, there is no treatment for Stargardt disease. Some ophthalmologists encourage people with Stargardt disease to wear dark glasses and hats when out in bright light to reduce the buildup of lipofuscin.
Get FREE sample copy at:
The Stargardt Disease (STGD) market report also covers emerging drugs, current treatment practices, Stargardt Disease (STGD) market share of the individual therapies, current and forecasted Stargardt Disease (STGD) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Stargardt Disease (STGD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Stargardt Disease (STGD) Market Key Facts
According to the estimates provided by the National Institute for Health, the reported prevalence of Stargardt disease is estimated to be 1 in 8,000 to 10,000 individuals.
- According to the Foundation Fighting Blindness, Stargardt disease is the most common form of inherited macular degeneration, affecting about 30,000 people in the U.S. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula.
Results from a study titled “The Epidemiology of Stargardt Disease in the United Kingdom” conducted by Kurt Spiteri Cornish et al. (n.d.) suggested an annual incidence of Stargardt disease between 0.110 and 0.128 per 100 000 individuals.
Key Benefits of Stargardt Disease (STGD) Market Report
Stargardt Disease (STGD) market report provides an in-depth analysis of Stargardt Disease (STGD) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Stargardt Disease (STGD) market report will help in developing business strategies by understanding the Stargardt Disease (STGD) Market trends & developments, key players, and future market competition that will shape and drive the Stargardt Disease (STGD) market in the upcoming years.
The Stargardt Disease (STGD) market report covers STGD’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Stargardt Disease (STGD) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Stargardt Disease (STGD) market size shall grow during the forecast period owing to the rise in the geriatric population leading to a rise in the number of people with Stargardt conditions along with emerging therapies.
The Stargardt Disease (STGD) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Stargardt Disease (STGD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Stargardt Disease (STGD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Stargardt Disease (STGD) Epidemiology
According to the American Institute of Ophthalmology, Stargardt Disease is the most commonly inherited childhood and adulthood maculopathy and has a prevalence of 1 in 10,000.
The Stargardt Disease (STGD) epidemiology section covers insights about the historical and current Stargardt Disease (STGD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Stargardt Disease (STGD) Drugs Uptake and Key Market Players
The Stargardt Disease (STGD) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stargardt Disease (STGD) market or expected to get launched in the market during the study period. The analysis covers Stargardt Disease (STGD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Research is underway to identify novel treatment approaches that may prove to be a way to support such patients. Some of the key players at the global level are involved in developing therapies for Stargardt’s disease.
Stargardt Disease (STGD) Companies:
Acucela Inc (Kubota)
Stargardt Disease (STGD) Therapies Covered in the Report Include:
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Stargardt Disease (STGD) Competitive Intelligence Analysis
4. Stargardt Disease (STGD) Market Overview at a Glance
5. Stargardt Disease (STGD) Disease Background and Overview
6. Stargardt Disease (STGD) Patient Journey
7. Stargardt Disease (STGD) Epidemiology and Patient Population
8. Stargardt Disease (STGD) Treatment Algorithm, Current Treatment, and Medical Practices
9. Stargardt Disease (STGD) Unmet Needs
10. Key Endpoints of Stargardt Disease (STGD) Treatment
11. Stargardt Disease (STGD) Marketed Products
12. Stargardt Disease (STGD) Emerging Therapies
13. Stargardt Disease (STGD) Seven Major Market Analysis
14. Attribute Analysis
15. Stargardt Disease (STGD) Market Outlook (7 major markets)
16. Stargardt Disease (STGD) Access and Reimbursement Overview
17. KOL Views on the Stargardt Disease (STGD) Market.
18. Stargardt Disease (STGD) Market Drivers
19. Stargardt Disease (STGD) Market Barriers
21. DelveInsight Capabilities
Stargardt Disease (STGD) Epidemiology Forecast
DelveInsight’s Stargardt Disease (STGD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Stargardt Disease (STGD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Stargardt Disease (STGD) Pipeline Insights
Stargardt Disease (STGD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Stargardt Disease (STGD) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States